Related Experiment Video
Updated: May 31, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Ramipril and risk of hyperkalemia in chronic hemodialysis patients
Mirna Krajina-Andricević1, Lada Zibar, Karin Juras
1Vinkovci General Hospital, Department of Internal Medicine, Vinkovci, Croatia. mirna.k1@hotmail.com
Abstract:
Angiotensin converting enzyme (ACE) inhibitors provide well known cardiorenal-protective benefits added to antihypertensive effects in chronic renal disease. These agents are underused in management of patients receiving hemodialysis (HD) because of common concern of hyperkalemia. However, few studies have investigated effect of renin angiotensin aldosterone system (RAAS) blockade on serum potassium in hemodialysis patients. We assessed the safety of ramipril in patients on maintenance HD. We enrolled 28 adult end stage renal disease (ESRD) patients treated by maintenance HD and prescribed them ramipril in doses of 1.25 to 5 mg per day. They underwent serum potassium concentration measurements before ramipril introduction and in 1 to 3 months afterwards. No significant increase in kalemia was found. Results of our study encourage the use of ACE inhibitors in chronically hemodialyzed patients, but close potassium monitoring is mandatory.
Related Concept Videos
Hemodialysis II: Procedure and Complications
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Chronic Kidney Disease III: Interprofessional Care
Acute Kidney Injury V: Interprofessional Care
Hemodialysis III: Nursing Management
Heart Failure Drugs: Diuretics